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Abstract
Objective—We aimed to report the frequency and implications of antibodies to myelin 
oligodendrocyte glycoprotein (MOG-ab) in adults with demyelinating syndromes suspicious for 
neuromyelitis optica (NMO).
Methods—Samples from 174 patients (48 NMO, 84 longitudinally extensive myelitis (LETM), 
39 optic neuritis (ON), and three acute disseminated encephalomyelitis (ADEM) who presented 
initially with isolated LETM) were retrospectively examined for AQP4-ab and MOG-ab using 
cell-based assays.
Results—MOG-ab were found in 17 (9.8%) patients, AQP4-ab in 59 (34%), and both antibodies 
in two (1.1%). Among the 17 patients with MOG-ab alone, seven (41%) had ON, five (29%) 
LETM, four (24%) NMO, and one (6%) ADEM. Compared with patients with AQP4-ab, those 
with MOG-ab were significantly younger (median: 27 vs. 40.5 years), without female 
predominance (53% vs. 90%), and the clinical course was more frequently monophasic (41% vs. 
7%) with a benign outcome (median Expanded Disability Status Scale: 1.5 vs. 4.0). In eight 
patients with paired serum-cerebrospinal fluid (CSF) samples, five had MOG-ab in both samples 
and three only in serum. Antibody titres did not differ among clinical phenotypes or disease 
course. MOG-ab remained detectable in 12/14 patients (median follow-up: 23 months) without 
correlation between titres' evolution and outcome.
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Conclusion—MOG-ab identify a subgroup of adult patients with NMO, LETM and ON that 
have better outcome than those associated with AQP4-ab. MOG-ab are more frequently detected in 
serum than CSF and the follow-up of titres does not correlate with outcome.
Keywords
Neuromyelitis optica; longitudinally extensive myelitis; optic neuritis; aquaporin-4 antibody; 
antibodies to myelin oligodendrocyte glycoprotein
Introduction
Aquaporin 4 antibodies (AQP4-ab) are useful biomarkers for neuromyelitis optica (NMO) 
and limited forms of the disease, including longitudinally extensive transverse myelitis 
(LETM) and recurrent optic neuritis (ON).1 Up to 30% of patients with NMO are AQP4-ab 
negative,2,3 it being unclear whether this group represents a different clinical entity.4 
Recently, antibodies to myelin oligodendrocyte glycoprotein (MOG-ab) were described in 
patients, usually children, with demyelinating syndromes.5 In children, MOG-ab are present 
in monophasic demyelinating diseases, mainly acute disseminated encephalomyelitis 
(ADEM),6–8 and less frequently in NMO and recurrent ON.9,10 Children with NMO and 
MOG-ab seem to have a more favourable outcome than those with AQP4-ab.8,9 Whether 
similar prognostic implications apply to adults with MOG-ab is currently unclear because 
the number of studies is limited and all of them included a mixed population of children and 
adults.11–13 The aim of the present study was to determine the frequency and implications of 
MOG-ab in adults with NMO and demyelinating syndromes suspicious for NMO.
Methods
Patients
Between November 2005 and November 2013 we examined 2348 serum samples of patients 
with demyelinating disorders sent to our laboratory to test AQP4-ab. We selected those that 
fulfilled these inclusion criteria: (1) age of the patient ≥ 18 years; (2) a definitive diagnosis 
of NMO according to Wingerchuk diagnostic criteria of 1999 or 2006,14,15 LETM,16 severe 
(visual acuity < 20/200) or bilateral or recurrent ON;17,18 and (3) available stored samples. 
Most of the samples, along with a standardized questionnaire with the clinical data, were 
referred by neurologists of the Spanish Group of Neuromyelitis optica18 and the Spanish 
Network of Multiple Sclerosis (Red Española de Esclerosis Múltiple, REEM).16 Positivity 
for MOG-ab was retrospectively determined. When outcome data were requested, the 
corresponding neurologists provided the information blinded to MOG-ab testing result. 
Relapses were defined as a new neurological symptoms lasting at least 24 h and 
accompanied by new neurological examination findings. Brain and spinal cord magnetic 
resonance imaging (MRI) features were not centrally reviewed. Overall, 174 adult patients 
were identified, including 48 with NMO, 84 LETM, 39 ON, and three patients who 
presented with isolated clinical findings of transverse myelitis and presence of LETM in the 
spinal cord MRI, but whose subsequent clinical evolution led to a final diagnosis of 
ADEM.19 All but seven patients were Caucasian. Thirty paediatric patients consecutively 
studied during the same period (four NMO, seven LETM, eight ON, 10 ADEM, and one 
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patient who developed a relapse of LETM 2 years after being diagnosed with multiple 
sclerosis (MS)) were used to compare the frequency of antibodies in both age groups. To 
evaluate the specificity of MOG-ab, sera of 55 adults with MS according to the McDonald 
criteria20 (20 with clinically isolated syndrome, 15 with relapsing–remitting MS, 10 with 
secondary progressive MS, and 10 with primary progressive MS) were included in the study. 
Serum and cerebrospinal fluid (CSF) samples used in the study are deposited in the 
collection of biological samples named “Neuroinmunología” registered in the Biobank of 
Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 
Informed consent for storage and use of these samples for research purposes was obtained 
from all patients. The study was approved by the Ethics Committee of the Hospital Clínic of 
Barcelona, Spain.
Cell-based assays
All samples were examined for AQP4-ab using an in-house cell-based assay (CBA) with live 
HEK293 cells transfected with the aquaporin-4-M23 isoform as previously reported21 (for 
more details see the Supplementary Material). MOG-ab were examined using an in-house 
CBA with HEK293 cells transfected with the full-length MOG C-terminally fused to EGFP 
as described previously22 (Supplementary Material and Supplementary Figure S-1). The titre 
of MOG-ab was obtained by serial dilutions of samples, starting at 1:160 for serum5 and 1:2 
for CSF until the reactivity was no longer visible. Intrathecal synthesis of MOG-ab and 
AQP4-ab was evaluated as described previously.23 To confirm the simultaneous presence of 
MOG- and AQP4-ab in two patients, serum samples were immunoabsorbed with pellets of 
HEK293 cells transfected with AQP4 or with MOG. Briefly, three P60 plates of confluent 
HEK293 cells transfected with the appropriate plasmid were scraped and spun down at 500 
g for 5 min. The pellets were resuspended and gently homogenized in DMEM (Invitrogen, 
Carlsbard, CA, USA) plus 10% FCS. Sera were diluted and incubated for 2 h at room 
temperature with the previous mix. A cleared supernatant was obtained by centrifugation at 
10,000 g for 10 min before the immunofluorescence assay.
Statistical analysis
Clinical data between groups were compared using nonparametric tests (Mann–Whitney U 
test) and the categorical data were analysed with Fisher's exact test and Chi-square test when 
appropriate. In patients with follow-up samples we analysed the association of titre change 
(a decrease of at least two serial dilutions or seronegative conversion between the first and 
the last sample) with monophasic course or outcome (Expanded Disability Status Scale 
score, EDSS, ≤ 2.0) with Fisher's exact test. Statistical significance was defined as two-sided 
p-value less than 0.05. The software used was IBM SPSS Statistics v19.
Results
MOG-ab were detected in 17/174 (9.8%) adult patients, AQP4-ab in 59 (34%) and both 
antibodies in two (1.1%). Seven of the 17 (41%) patients with isolated MOG-ab had ON, 
five (29%) LETM, four (24%) NMO, and one (6%) ADEM (Table 1). The frequency of 
MOG-ab and AQP4-ab varied according to the clinical phenotype: MOG-ab occurred less 
frequently than AQP4-ab in NMO (8.7% vs. 80%, p < 0.001) and LETM (6% vs. 19%, p = 
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0.017), and were similarly frequent in ON (18% vs. 15%, p = 1.0). In comparison, paediatric 
patients had a similar frequency of antibodies but with a predominance of MOG-ab found in 
12 patients (one also with AQP4-ab) whereas only one patient had AQP4-ab. The most 
common clinical phenotype was ADEM, diagnosed in 36% of paediatric patients. Control 
adult MS patients were MOG-ab negative.
The demographic and clinical features of MOG-ab or AQP4-ab seropositive and 
seronegative patients are shown in Table 1. The two patients with both antibodies presented 
with a classic NMO clinical picture of simultaneous bilateral ON and LETM and were 
excluded from analysis. Patients with isolated MOG-ab were different from those with 
AQP4-ab with respect to predominance of women (53% vs. 90% female, p = 0.002), age at 
onset (median 27 vs. 40.5 y, p = 0.017), monophasic course (41% vs. 7%, p = 0.002), use of 
chronic therapy (35% vs. 91%, p < 0.001) and disability at the last follow-up (median EDSS, 
1.5 vs. 4.0, p < 0.001). Patients with MOG-ab were also different from seronegative patients 
with respect to age at onset (median 27 vs. 37.5 y, p = 0.021) and disability at last visit 
(median EDSS 1.5 vs. 3.0, p < 0.001). The clinical features of each patient with MOG-ab are 
shown in Table 2.
Patients received similar acute treatments regardless of antibody status. All but one patient 
(94%) with isolated MOG-ab were treated with IV methylprednisolone (IVMP) (1 g/d for 3–
5 days) and four of them (24%) additionally underwent plasma exchange (PLEX). Similarly, 
50/59 (84.7%) of the AQP4-ab positive and 70/86 (82%) of the seronegative patients 
received IVMP as acute first-line treatment (p = 0.44 and p = 0.29, respectively). The 
percentage of patients that additionally underwent PLEX was also similar: 11/59 (19%) of 
the AQP4-ab positive (p = 0.73) and 13/86 (15%) of the seronegative patients (p = 0.47) 
(Table 1).
Representative cases including the two NMO patients harbouring both antibodies are 
described in the supplemental material: eAppendix.
Comparison of MOG-ab positive patients according to clinical phenotypes
MOG-ab were detected in 4/9 (44%) of NMO and 5/84 (6%) of LETM patients without 
AQP4-ab (Table S-1 and S-2 in supplemental material). NMO patients with MOG-ab 
compared with those with AQP4-ab had a better outcome with a significant lower EDSS at 
the last visit (median EDSS 1.8 vs. 4.0, p = 0.023), despite both groups having a similar 
relapsing course (Table S-1 in supplemental material). LETM patients with MOG-ab 
compared with those with AQP4-ab were younger (median 36 vs. 46 y, p = 0.05), and they 
had a more frequent monophasic course (80% vs. 14%, p = 0.017). Compared with 
seronegative patients, those with LETM and positive MOG-ab had a higher frequency of 
involvement of all spinal cord regions (40% vs. 3%, p = 0.029) and a lower disability 
(median EDSS 2.0 vs. 4.0, p = 0.043). Although the severity of the initial episode of LETM 
was similar in patients with MOG-ab, AQP4-ab and seronegative cases, the outcome of 
patients with MOG-ab was better (Table S-2 in supplemental material). In fact, on follow-up 
imaging, in 7/8 (87%) MOG-ab patients with NMO and LETM, the spinal cord MRI showed 
a complete resolution (in 5) or reduction of the lesion to < 2 vertebral segments (in 2), a 
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feature only observed in 4/20 (20%) of AQP4-ab positive patients (p = 0.002) and 8/23 
(35%) of seronegative patients (p = 0.016).
MOG-ab were found in 7/39 (18%) of ON patients, accounting for 21% of the seronegative 
AQP4-ab patients (Table S-3 in supplemental material). MOG-ab patients compared with 
those with AQP4-ab had a higher frequency of relapses and lower disability, although 
because of the small numbers the differences were not significant (p = 0.058 and p = 0.052, 
respectively), and compared with seronegative patients had a significant lower disability 
(median EDSS 1.0 vs. 3.5, p = 0.010) (Table S-3 in supplemental material). The optic nerve 
appeared to be a main target in the immune attack associated with MOG-ab because 38/41 
(93%) recurrences seen in patients with MOG-ab were ON (the optic nerve to spinal cord 
ratio involvement was 12.7:1). Moreover, in the group of NMO and MOG-ab, 9/11 (82%) 
relapses were ON, which was similar to the frequency seen in seronegative NMO patients 
8/11 (73%) (p = 1.0). By contrast, in AQP4-ab-positive NMO patients ON occurred in 37/77 
(48%) relapses (p = 0.052).
Serological characteristics of MOG-ab positive patients and clinical course
In 10 out of 19 patients with MOG-ab the initial serum or CSF samples were collected at 
disease onset and in the other nine patients during remission after a median of 74 months 
from onset (range 8–324 months; IQR 12.5–180) (Supplementary Figure S-2). The antibody 
titres were similar regardless of the time of sample collection, clinical phenotype, or 
subsequent disease course (relapsing vs. monophasic course). Follow-up samples were 
obtained in 14/19 (73.6%) patients with MOG-ab (including the two patients with double 
seropositivity) after a median follow-up of 23 months (range 5–120 months; IQR 11.8–89.5; 
five patients ≥ 6 years). MOG-ab titres remained unchanged in six patients, decreased at 
least two dilutions in six, and became negative in two (in a case with ADEM 6 months after 
disease onset, and in a case with NMO 1 year after disease onset). The samples from the five 
patients with more than 5 years of follow-up remained antibody positive (median titre, 
1:640, range 1:320–1:640). The decrease of MOG-ab titres was not associated with a 
monophasic course or better outcome (p = 0.1). Paired serum and CSF samples were 
available from eight patients with MOG-ab; antibodies were found only in serum of three 
patients (one NMO and two ON) and in serum and CSF of the other five (three NMO, one 
LETM, and one ON). Two of these five patients had values suggestive of intrathecal 
synthesis23 of MOG-ab and another patient of both MOG and AQP4-ab. In one NMO 
patient with a 10-year follow-up, MOG-ab were still positive in the serum (1:320), while 
CSF was negative (supplementary eFigure 2).
Discussion
In this series we show that 10% of all adults with demyelinating syndromes suspected to be 
related to AQP4-ab had MOG-ab, and that the frequency of MOG-ab went up to 15% when 
all patients without AQP4-ab were considered. Characterization of the underlying immune 
response is important because compared with patients with AQP4-ab, those with MOG-ab 
were younger, more frequently had a monophasic disease, and were associated with a more 
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benign outcome. Moreover, irrespective of the clinical syndrome, patients with MOG-ab 
were less disabled and most of them were free of medication 5 years after disease onset.
ON was the more frequent syndrome associated with MOG-ab, emphasizing that the optic 
nerve is a main target involved in the immune attack.11–13 Six of seven patients with isolated 
ON had a relapsing course, whereas a monophasic course was seen in the single case who 
developed bilateral simultaneous ON.13 A previous study described MOG-ab in five patients 
with ON; all of them had recurrent ON with a comparable frequency of relapses (median 
three, range 3–16) but the clinical characteristics were not provided.12 In the current study, 
despite the severity of the ON at symptom onset and the high frequency of relapses, patients 
had minimal visual acuity impairment after a median follow-up of 96 months, supporting the 
idea of a better recovery associated with the presence of MOG-ab.
We identified AQP4-ab in only 19% of patients with LETM; this is in contrast with the 
frequencies of 58% and 89% reported in two studies by other investigators using a similar 
sensitive method of detection.24,25 These discordant figures are likely explained by selection 
bias. In the first study,24 32% (14/44) of AQP4-ab positive patients had history of ON or 
Devic's phenotype at disease onset. Our study, however, only included patients with isolated 
LETM. In the second study,25 all 48 patients had recurrent episodes of LETM, a feature 
associated with AQP4-ab. In contrast, in our series only 46% of the patients had a relapsing 
course. Although one could infer that the lack of relapses provides an explanation for the 
better outcome of patients with MOG-ab compared with those with AQP4-ab,11–13 other 
underlying factors might be involved given that seronegative LETM patients in our study 
had a worse prognosis despite 60% being monophasic. Moreover, the severity of the 
symptoms observed during the episode of LETM (EDSS nadir score) was similar regardless 
of the serological status; this finding and the fact that the three groups of patients were 
treated with similar immunotherapy and plasma exchange suggest that MOG-ab associate 
with better recovery.
Previous reports suggested that the occurrence of simultaneous ON and LETM along with a 
monophasic course is characteristic of NMO associated with MOG-ab.11,13 However, our 
experience here shows that only one of the four NMO patients with MOG-ab had these 
clinical features, and simultaneous ON and LETM along with a monophasic course were 
also found in 1/9 NMO patients with AQP4-ab and 1/2 seronegative NMO patients.
In addition to the above-discussed clinical associations, our study provides several novel 
concepts related to antibody titres: (1) the titres of MOG-ab were similar in patients with 
different syndromes (NMO, LETM, or ON), and did not differ substantially in patients with 
monophasic or relapsing disease, or in samples obtained at symptom presentation or during 
remission; (2) detection of MOG-ab can persist for several years (e.g. > 5 years) while 
patients are free of relapses; (3) MOG-ab seems to occur more frequently in serum than in 
CSF; (4) intrathecal synthesis of MOG-ab appears infrequent and may not be associated 
with a different outcome; and (5) the coexistence of MOG-ab and AQP4-ab in only one 
paediatric and two adult patients with NMO of our series, and a previously reported case 
with NMO,12 indicate that this association is very rare.
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Overall, MOG-ab identify a subgroup of patients with NMO or suspected limited forms of 
the disease who have better outcome than AQP4-ab positive patients or seronegative 
patients. Although the percentage of patients with MOG-ab is small, their recognition has 
important clinical and prognostic implications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Comparison of demographic and clinical features between seropositive (MOG-ab or AQP4-ab) and 
seronegative patients.
Patients characteristics n=174









a 4 (24) 37 (63) 5 (5) 0.006 0.028
 LETM (84) 5 (29) 16 (27) 63 (66) 1.00 0.007
 ON (39) 7 (41) 6 (10) 26 (27) 0.007 0.256
 ADEM (3) 1 (6) 0 2 (2) 0.224 0.389
Female, n (%) 9 (53) 53 (90) 63 (66) 0.002 0.412
Age at onset, y, median (range) 27 (18–59) 40.5 (18–73.5) 37.5 (18–76.5) 0.017 0.021
Coexisting autoimmune disorders, n (%) 1 (6) 9/56 (16) 9/77 (11.5) 0.435 1.00
Simultaneous ON+myelitis attacks at onset, 
n (%)
3 (18) 9 (15) 2 (2) 0.811 0.024
Nadir EDSS score, median (range) 4.0 (3.0–8.0) 6.0 (2.0–8.0) 5.0 (3.0–9.0) 0.782 0.623
MRI brain classification
 Normal 13 (76) 31/57 (54) 52/81 (64) 0.159 0.407
 Nonspecific 4 (24) 22/57 (39) 27/81(33) 0.386 0.570
 MS-like 0 4/57 (7) 2/81 (3) 0.568 1.00
MRI cord lesion
 Median vertebral segments (range) 5 (3–21) 5 (2–23) 6 (3–23) 0.674 0.991
CSF
 WBC > 50/mm3, n (%) 4/16 (25) 4/39 (10) 11/64 (17) 0.211 0.485
 OCBs, n (%) 1 (6) 5/44 (11) 10/62 (16) 1.00 0.445
ANA, n (%) 6 (35) 29 (49) 44/92 (48) 0.408 0.431
Acute treatment
 IVMP + PE, n (%) 4 (24) 11 (19) 13/86 (15) 0.732 0.474
Monophasic course, n (%) 7 (41) 4/57 (7) 54 (56) 0.002 0.297
No. of attacks, median (range) 3 (1–14) 3 (1–14) 2 (1–18) 0.743 0.139
Time to first relapse, mo, median (range) 7.5 (1–160) 8 (1–144) 6 (1–123) 0.989 0.650
Chronic treatment, n (%) 6 (35) 49/54 (91) 34/92 (37) <0.001 1.00
Last EDSS, median (range) 1.5 (0–3.0) 4.0 (0–10) 3.0 (0–8.5) <0.001 <0.001
Follow-up, mo, median (range) 67 (11–415) 65 (1–355) 30 (1–175) 0.812 0.010
MOG-ab: antibodies to myelin oligodendrocyte glycoprotein; AQP4-ab: aquaporin 4 antibodies; NMO: neuromyelitis optica; LETM: longitudinal 
extensive transverse myelitis; ON: optic neuritis; ADEM: acute disseminated encephalomyelitis; EDSS: Expanded Disability Status Scale; CSF: 
cerebrospinal fluid; WBC: white blood cells; OCBs: oligoclonal bands; ANA: antinuclear antibody; IVMP: intravenous methylprednisolone; PE: 
plasma exchange.
a
Two NMO patients with both MOG-ab and AQP4-ab were excluded from analysis.
b
Comparison between MOG-ab+ and AQP4-ab+ patients;
c
Comparison between MOG-ab+ and seronegative patients.
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